Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients

Arvinas and Pfizer’s targeted protein degrader has not managed to distinguish itself from other, similar breast cancer drugs, according to pivotal data released Tuesday. Results of the Phase 3 VERITAC-2 trial show that vepdegestrant extended ...